{"title":"罕见变异关联研究揭示了 HCC 的致命弱点。","authors":"Yin Wang, Ying Wai Chan","doi":"10.1016/j.xgen.2024.100558","DOIUrl":null,"url":null,"abstract":"<p><p>In this issue of Cell Genomics, Wang, Liu, Zuo, Wang, et al.<sup>1</sup> investigate rare variants in hepatocellular carcinoma (HCC) by performing the first rare-variant association study (RVAS) in a Chinese population cohort. It uncovers BRCAness phenotypes associated with the NRDE2-p.N377I variant, suggesting PARP inhibitors as a promising therapeutic approach for certain HCC patients.</p>","PeriodicalId":72539,"journal":{"name":"Cell genomics","volume":"4 5","pages":"100558"},"PeriodicalIF":11.1000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11099380/pdf/","citationCount":"0","resultStr":"{\"title\":\"Rare-variant association study unveils the Achilles' heel for HCC.\",\"authors\":\"Yin Wang, Ying Wai Chan\",\"doi\":\"10.1016/j.xgen.2024.100558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this issue of Cell Genomics, Wang, Liu, Zuo, Wang, et al.<sup>1</sup> investigate rare variants in hepatocellular carcinoma (HCC) by performing the first rare-variant association study (RVAS) in a Chinese population cohort. It uncovers BRCAness phenotypes associated with the NRDE2-p.N377I variant, suggesting PARP inhibitors as a promising therapeutic approach for certain HCC patients.</p>\",\"PeriodicalId\":72539,\"journal\":{\"name\":\"Cell genomics\",\"volume\":\"4 5\",\"pages\":\"100558\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2024-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11099380/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell genomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xgen.2024.100558\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.xgen.2024.100558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
Rare-variant association study unveils the Achilles' heel for HCC.
In this issue of Cell Genomics, Wang, Liu, Zuo, Wang, et al.1 investigate rare variants in hepatocellular carcinoma (HCC) by performing the first rare-variant association study (RVAS) in a Chinese population cohort. It uncovers BRCAness phenotypes associated with the NRDE2-p.N377I variant, suggesting PARP inhibitors as a promising therapeutic approach for certain HCC patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
